NPC

Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1

Retrieved on: 
Thursday, May 30, 2024

The TransportNPC™ study is the most comprehensive controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes of an investigational therapy for NPC1.

Key Points: 
  • The TransportNPC™ study is the most comprehensive controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes of an investigational therapy for NPC1.
  • Additionally, the Company has enrolled ten (10) patients in its substudy per their adopted Paediatric Investigational Plan (PIP) treating newborn to 3 years of age.
  • “The completion of enrollment represents by far the most significant milestone for Cyclo Therapeutics to date.
  • For more information about the Company’s TransportNPC™ pivotal Phase 3 study, visit www.ClinicalTrials.gov and reference identifier NCT04860960 .

U.S. Polo Assn. Named Finalist as Best Sports Licensed Brand at the 2024 Licensing International Excellence Awards

Retrieved on: 
Thursday, May 23, 2024

West Palm Beach, FL, May 23, 2024 - (ACN Newswire) - U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce the brand's nomination as a finalist for Best Sports Licensed Brand at the prestigious 2024 Licensing International Excellence Awards.

Key Points: 
  • West Palm Beach, FL, May 23, 2024 - (ACN Newswire) - U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce the brand's nomination as a finalist for Best Sports Licensed Brand at the prestigious 2024 Licensing International Excellence Awards.
  • was among notable brands such as Formula 1, NASCAR, the NFL Players Association, 24H LE MANS, and Yale University in the category for Best Sports Licensed Brand.
  • is honored to be named alongside other industry leaders in the 2024 Licensing International Excellence Awards, and we congratulate the winner for their performance this year!"
  • "It's an honor to be recognized as a finalist for the Best Sports Licensed Brand.

The cybersecurity capital of Philippines, PhilSec now an essential choice for critical infrastructure

Retrieved on: 
Monday, May 20, 2024

A mecca for both cybersecurity aficionados and solution-seeking organisations, the platform has made a name for putting a grand showcase of the latest cybersecurity products.

Key Points: 
  • A mecca for both cybersecurity aficionados and solution-seeking organisations, the platform has made a name for putting a grand showcase of the latest cybersecurity products.
  • He stated, "If we're not continuously on the offensive, testing every link in our cybersecurity value chain, then we are inviting disaster.
  • With numerous partnerships and collabs being forged every year, PhilSec is now the leading choice for all public & private sector organisations that are trying to up their cybersecurity game.
  • As we usher in a new era of cybersecurity, this inclusive platform will bring diverse stakeholders closer, all the while doing wonders for Philippines' critical infrastructure."

NeuralAI Launches AI 3D Asset Generator with TAO Bittensor Subnet: Transforming 3D Model Creation for Games and Beyond

Retrieved on: 
Tuesday, May 28, 2024

NeuralAI leverages advanced generative artificial intelligence to enable text-to-3D and image-to-3D conversions, significantly reducing the costs, time, and complexity traditionally associated with 3D model creation.

Key Points: 
  • NeuralAI leverages advanced generative artificial intelligence to enable text-to-3D and image-to-3D conversions, significantly reducing the costs, time, and complexity traditionally associated with 3D model creation.
  • This technology promises to supercharge the development of games, movies, and a wide array of creative industries.
  • AI 3D Asset Generation: NeuralAI’s dApp allows users to transform textual prompts or images into vivid 3D assets.
  • TAO Mining GPU Rentals: In collaboration with the AKASH Network, NeuralAI offers GPU power rentals configured with ready TAO miner templates.

Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 16, 2024

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2024 and provided a business update.

Key Points: 
  • Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2024 and provided a business update.
  • Granted U.S. patent covering use of Trappsol® Cyclo™ for treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office.
  • Net loss for the quarter ended March 31, 2024 was approximately $4.3 million.
  • Research and development expenses decreased 16% to $2.8 million for the quarter ended March 31, 2024, from $3.4 million for the quarter ended March 31, 2023.

Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral Presentation and Two Posters.

Retrieved on: 
Monday, May 13, 2024

NANJING, China, May 13, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024.

Key Points: 
  • NANJING, China, May 13, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024.
  • Leads Biolabs will present the exciting clinical data on its four innovative clinical programs at the ASCO meeting.
  • LBL-024 received IND approvals from FDA and NMPA on July 30, 2021 and September 9, 2021 respectively to conduct phase Ⅰ/Ⅱ clinical research.
  • Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said "Leads Biolabs will be presenting four clinical projects at 2024 ASCO.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
Friday, May 10, 2024

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

Retrieved on: 
Friday, May 10, 2024

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.

Key Points: 
  • CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043.
  • This landmark achievement marks the world's first approval of an EB virus-related mRNA therapeutic cancer vaccine.
  • The FDA approval of WGc-043 represents a significant advance in cancer treatment, offering new hope to patients with advanced EB virus-related cancers.
  • EB virus is highly correlated with more than ten malignancies, including nasopharyngeal carcinoma (NPC), natural killer T-cell lymphoma (NKTL), gastric cancer, lung cancer, liver cancer, esophageal cancer, breast cancer, cervical cancer, and autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus.

2024 U.S. Open Polo Championship(R) Closes Out Historic High-Goal Season at the Sport's Premier Destination in Palm Beach County, Florida

Retrieved on: 
Tuesday, April 23, 2024

WELLINGTON, FL, Apr 23, 2024 - (ACN Newswire) - The 2024 U.S. Open Polo Championship(R) has officially closed out the American high-goal polo season at the USPA National Polo Center (NPC), the sport's premier destination.

Key Points: 
  • WELLINGTON, FL, Apr 23, 2024 - (ACN Newswire) - The 2024 U.S. Open Polo Championship(R) has officially closed out the American high-goal polo season at the USPA National Polo Center (NPC), the sport's premier destination.
  • The U.S. Open Polo Championship is universally considered the most prestigious tournament in the United States and showcases some of the world's best polo players and equine athletes.
  • brand supported the historic U.S. Open Polo Championship by co-branding jerseys for teams, elevating NPC staff uniforms, umpire outfitting, player prizes, and monetary donations to several charities.
  • "Congratulations to La Dolfina on an incredibly well-fought victory in one of the sport's most historic tournaments, the U.S. Open Polo Championship.

Global Sports Brand U.S. Polo Assn. Delivers Record $2.4 Billion in Retail Sales for 2023, Targets $3 Billion and 1,500 U.S. Polo Assn. Stores

Retrieved on: 
Tuesday, April 2, 2024

The global sports brand's record growth is the result of expanding its existing sizeable footprint across all regions around the world.

Key Points: 
  • The global sports brand's record growth is the result of expanding its existing sizeable footprint across all regions around the world.
  • In fact, the brand is targeting to become a billion-dollar business in India alone, as U.S. Polo Assn.
  • The brand's footprint is a fast-growing presence across 190 countries, with over 1,100 U.S. Polo Assn.
  • retail stores and thousands of wholesale locations spanning department stores, sporting goods channels, and independent retailers, as well as e-commerce.